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Available online 11 June 2016A 48-year-old woman underwent a total abdominal hysterectomy after preoperative diagnosis of multiple uter-
ine leiomyomas. The histopathological diagnosiswas leiomyosarcoma (LMS). After 47months,multiple lungme-
tastaseswere detected and resected. The patientwas also diagnosedwith pelvic bonemetastasis and received six
cycles of adjuvant chemotherapywith gemcitabine plus docetaxel and local radiation therapy to control the pain.
Seventy-seven months from the initial diagnosis, she had a headache and developed left hemiparesis and apha-
sia. Imaging studies detected a solitary brain metastasis in the right frontal lobe. The patient underwent a crani-
otomy and resection of the lesion, which was a conﬁrmed metastasis from uterine LMS by histopathology. One
month after the craniotomy, the patient experienced lower abdominal pain, and a pelvicmetastasiswas detected.
She was prescribed oral pazopanib (800mg per day). For twelvemonths, she remained asymptomatic, but grad-
ually, pelvic pain increased due to pelvic mass growth. After 14 months of pazopanib treatment, pazopanib was
discontinued. Todate, for 18months after the brain surgery, she is alivewith disease, and thebrainmetastasis has
not recurred.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Pazopanib1. Introduction
Brain metastasis of uterine leiomyosarcoma (LMS) is rare (Wroński
et al., 1994 Aug; Honeybul & Ha, 2009 Mar; Yamada et al., 2011 Dec;
Rose et al., 1989 Mar 1; Fleming et al., 1984 Oct). Several case reports
suggest a resection of brain metastases of uterine LMS could result in
longer survival, for which controlling systemic disease is a prerequisite
(Wroński et al., 1994 Aug; Honeybul & Ha, 2009 Mar; Yamada et al.,
2011 Dec; Gadducci et al., 1996 Jul). However, adjuvant therapies after
brain surgery have not been established. Radiotherapy after brain sur-
gery can lower recurrence rates, but long-term toxic side effects of radi-
ation, such as cognitive decline, decrease quality of life, and radiation
cannot control systemic disease. Pazopanib is approved for soft tissue
sarcomas and penetrates the blood-brain barrier (BBB) (Iwamoto
et al., 2010 Aug). Several case reports in other malignancies suggest
that pazopanib treatment could elicit survival beneﬁts for patients
with brain metastases in addition to controlling systemic disease
(Jacobs et al., 2013 Mar 1; Hingorani et al., 2014). We present the ﬁrst
case report of long-term disease stabilizationwith pazopanib treatment
after a resection of solitary brain metastasis from uterine LMS.. Inoue).
. This is an open access article under2. Case report
A 48-year-old multiparous woman underwent a total abdominal
hysterectomy for what was thought to bemultiple uterine leiomyomas.
Final histopathology revealed uterine LMS, and she was referred to our
hospital.
Subsequent positron emission tomography/computed tomography
(PET/CT) showed no metastatic lesions, and she was followed up with-
out further surgery or adjuvant therapy. Forty-seven months after the
initial diagnosis, a biannual follow-up computed tomography (CT)
scan revealedmultiple lungmetastases, and video-assisted thoracic sur-
gery (VATS) was performed. The surgical specimens were conﬁrmed
LMS metastases. Shortly after the VATS procedure, the patient devel-
oped pelvic pain, and PET/CT imaging suggested a pelvic bonemetasta-
sis. She was treated with six cycles of adjuvant chemotherapy with
gemcitabine and docetaxel, and local radiation therapy was adminis-
tered to control the pain. Seventy-sevenmonths after the initial diagno-
sis, she had a gradually worsening headache, and 2 weeks later, she
developed left hemiparesis and aphasia with a Karnofsky performance
scale (KPS) score of 40. Magnetic resonance imaging (MRI) revealed a
solitary 58 mm × 45 mm lesion in the right frontal lobe with a midline
shift (Fig. 1). The patient underwent a craniotomy and complete resec-
tion of the lesion, after which she showed no neurological deﬁcit, and
her KPS score improved to 90. Immunohistochemical ﬁndings of the
resectedmetastatic brain tumorwere positive for alpha-smoothmusclethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.MRI images of the solitary brain metastatic lesion in the right frontal lobe. A: T1 image, B: T2 image, C and D: Gadolinium-enhanced MRI.
Fig. 2. Microscopic ﬁndings of the resected metastatic brain tumor. Marked cellular
pleomorphism, nuclear atypia, and mitotic ﬁgures are present. A: Hematoxylin and
eosin (H&E), ×20, B: The inset of A, ×40.
61K. Inoue et al. / Gynecologic Oncology Reports 17 (2016) 60–64actin, vimentin, desmin, and epithelial membrane antigen staining, and
LMS metastasis to the brain was conﬁrmed (Figs. 2 and 3). One month
after the craniotomy, she experienced lower abdominal pain that re-
quired opioids, and a CT scan revealed a pelvicmass that was suggestive
of recurrence and was unresectable (Fig. 4). The patient was informed
about an increased risk for intracranial hemorrhage by using pazopanib.
One month after the brain surgery, she began oral pazopanib (800 mg
per day). One month later, she was free of pain, and no opioid was nec-
essary. She experienced mild diarrhea and mild hypertension, both of
which were well-controlled.
For 12 months, the patient remained asymptomatic. There was no
recurrence of brain metastasis. However, the pelvic lesions gradually
enlarged, causing a severe pain. Therefore, 14 months after starting
pazopanib, it was discontinued. To date, she remains alive with disease,
18 months after the brain surgery.
3. Discussion
Uterine LMS is aggressive in nature, and prognosis of recurrent LMS
is very poor. The risk of recurrence after complete resection of uterus-
limited LMS, whichwas estimated to be 70% after 2 years in a retrospec-
tive study, is high (Major et al., 1993 Feb 15). Themost common sites of
uterine LMSmetastasis are the lung, pelvis, and vagina (Rose et al., 1989
Fig. 3. Immunohistochemicalﬁndings of the resectedmetastatic brain tumor. A: Alpha-smoothmuscle actin staining, ×20. B: Vimentin staining, ×20. C:Desmin staining, ×20. D: Epithelial
membrane antigen (EMA) staining, ×20.
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best of our knowledge, only case reports of uterine LMS metastasis to
the brain are available (Wroński et al., 1994 Aug; Honeybul & Ha,
2009 Mar; Yamada et al., 2011 Dec). Yamada et al. reviewed in their
case report that there had been 21 such cases (Yamada et al., 2011
Dec). Brain metastasis incidence has been reported to be 1 in 19 (Rose
et al., 1989 Mar 1) and 1 in 4 from autopsies of patients with uterine
LMS (Fleming et al., 1984 Oct). In a retrospective study of brain metas-
tases from gynecologicmalignancies, 4 cases out of 139 cases of gyneco-
logic malignancies were uterine LMS (Nasu et al., 2013 Feb). Because of
its rarity, there has been no established management for uterine LMS
metastasis to the brain.
For recurrence of uterine LMS, combination chemotherapy, such as
gemcitabine and docetaxel, may be a treatment option (Hensley et al.,
2002 Jun 15), but it is meant to be palliative and is not curative. Addi-
tionally, conventional cytotoxic agents that have proven to be effective
for LMS do not cross the BBB. Only surgical resection can prolong surviv-
al. In a retrospective study by Leitao et al., pulmonary and extrathoracic
metastasectomy of recurrent uterine LMS resulted in a survival beneﬁt
when complete resection was achieved (Leitao et al., 2002 Dec). In
cases of a solitary brain metastasis of uterine LMS with well-controlled
systemic disease, long-term survival, namely 1–2 years, after brain
surgery can be expected, as presented and reviewed in multiple case
reports (Wroński et al., 1994 Aug; Honeybul & Ha, 2009 Mar; Yamada
et al., 2011 Dec; Gadducci et al., 1996 Jul). On the other hand, in patients
with progressive and uncontrolled systemic metastases, survival is very
poor, even after an aggressive brain surgery (Honeybul &Ha, 2009Mar).
Moreover, whole-brain radiotherapy (WBRT) after brain surgery can
greatly lower brain metastasis recurrence rates (Patchell et al., 1998
Nov 4), but long-term toxic effects of WBRT, such as cognitive decline,
should be considered when systemic disease remains under controland long-term survival is expected. Yamada et al. pointed out that in
patients with uterine LMS metastasis to the brain, postoperative radia-
tion therapy might not offer survival beneﬁts (Yamada et al., 2011
Dec). Furthermore, when brainmetastasis recurrence can be decreased,
systemic disease should be controlled. Adjuvant therapy that is effective
for both systemic and brain-speciﬁc disease after brain surgery is
needed.
Pazopanib is a multi-targeted tyrosine kinase inhibitor that impairs
angiogenesis and is approved for soft tissue sarcoma treatment. It is
small enough to penetrate the BBB and has been used in a phase II
study for patients with glioblastoma (Iwamoto et al., 2010 Aug). One
case report showed prolonged survival after pazopanib therapy for pa-
tients with papillary renal cell carcinoma and brain metastases (Jacobs
et al., 2013 Mar 1). Another case report described a patient with renal
cancer and brain metastasis who survived for 3 years after WBRT and
subsequent pazopanib (Hingorani et al., 2014). Pazopanib was used to
treat the patient in our case report to control the pelvic lesions and pre-
vent brain metastasis recurrence. It was well-tolerated, and to date,
there has been no brain metastasis recurrence, and, although they
have since progressed, the pelvic lesions remained under control for a
year.
We can study the role of pazopanib by relieved symptoms, tumor
size reduction assessed by imaging studies including ultrasonography,
CT and MRI, and treatment response assessed by ﬂuorodeoxyglucose
PET/CT (except for brain metastases). If resected specimens are obtain-
ed, the immnohistochemical expression of platelet-derived growth fac-
tor receptor (PDGFR) can be investigated as a predictive marker for
response of pazopanib, although it has not been clinically applicable.
As for brain metastasis, resectable uterine leiomyosarcoma metastatic
to the brain is very rare, and to the best of our knowledge, immunohis-
tochemical investigation has not proceeded.
Fig. 4. CT images of the lung and pelvis. A and B:Multiple smallmetastatic lesions in bilateral lungﬁelds on chest CT. C: A cystic lesion in the left pelvis. D: A 5-cm tumor and a lytic lesion of
the pubic bone.
63K. Inoue et al. / Gynecologic Oncology Reports 17 (2016) 60–64It is unknown whether pazopanib was actually effective for
preventing recurrence of brain metastasis or whether complete resec-
tion of the brain metastasis contributed to the favorable prognosis in
this patient. The patient enjoyed a prolonged symptom-free survival
from the surgery for the brain metastasis.4. Conclusion
Long-term disease stabilization was obtained with pazopanib treat-
ment after resection of a uterine LMS brain metastasis. Pazopanib, with
its ability to penetrate the BBB, could replace WBRT after resection of
solitary brain metastasis and might lower brain metastasis recurrence
rates and control systemic disease.Disclosure
Written informed consent for this report was obtained from the pa-
tient. The authors have no conﬂicts of interest to declare.References
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